1 active not recruiting, 1 terminated. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
Follow HiDAC: new trials by email Literature Review of HiDAC trials Research Report on HiDAC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias Revumenib, Chemotherapy Regimen, HiDAC - Acute Myeloid Leukemias | Phase 1 | Active not recruiting | Syndax Pharmaceuticals | 96 | 2024-05-21 | 2026-09-16 |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Ficlatuzumab, Cytarabine - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Terminated | C. Babis Andreadis | 17 | 2015-05-01 | 2020-03-24 |
C. Babis Andreadis (1) · Syndax Pharmaceuticals (1)
United States (2) · Australia (1) · Canada (1) · Netherlands (1) · Spain (1) · United Kingdom (1)